Interleukin-15-mediated inflammation promotes non-alcoholic fatty liver disease

Cytokine

Volumn 82, Issue , 2016, Pages 102-111

  Cepero Donates, Yuneivy ^a   Lacraz, Grégory ^a,b   Ghobadi, Farnaz ^a   Rakotoarivelo, Volatiana ^a   Orkhis, Sakina ^a   Mayhue, Marian ^a   Chen, Yi Guang ^c   Rola Pleszczynski, Marek ^a,d   Menendez, Alfredo ^a,d   Ilangumaran, Subburaj ^a,d   Ramanathan, Sheela ^a,d  

^a UNIVERSITÉ DE SHERBROOKE   (Canada)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

^d CRCHUS   (Canada)

Author keywords

Inflammation; Interleukin 15; Liver; Mice; NAFLD

Indexed keywords

GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 15; INTERLEUKIN 15 RECEPTOR ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; RANTES; CHEMOKINE; IL15RA PROTEIN, MOUSE; INTERLEUKIN 15 RECEPTOR;

ADIPOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DIFFERENTIATION; CELL EXPANSION; CELL INFILTRATION; CONTROLLED STUDY; FATTY ACID METABOLISM; GENE EXPRESSION; IMMUNOPATHOGENESIS; IN VITRO STUDY; LIPID STORAGE; MALE; MITOCHONDRIAL RESPIRATION; MONONUCLEAR CELL; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; UPREGULATION; ANIMAL; CD8+ T LYMPHOCYTE; CHEMICALLY INDUCED; FAT INTAKE; GENETICS; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; INFLAMMATION; KNOCKOUT MOUSE; LIVER CELL; NATURAL KILLER CELL; PHARMACOLOGY;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CHEMOKINES; DIETARY FATS; HEPATOCYTES; IMMUNOLOGIC MEMORY; INFLAMMATION; INTERLEUKIN-15; KILLER CELLS, NATURAL; MICE; MICE, KNOCKOUT; NON-ALCOHOLIC FATTY LIVER DISEASE; RECEPTORS, INTERLEUKIN-15;

EID: 84956921610     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2016.01.020     Document Type: Article

References (68)

1. Ahmed M. Non-alcoholic fatty liver disease in 2015. World J. Hepatol. 2015, 7:1450-1459.
2. Lazo M., Hernaez R., Eberhardt M.S., Bonekamp S., Kamel I., Guallar E., et al. Prevalence of nonalcoholic fatty liver disease in the United States: the third national health and nutrition examination survey, 1988-1994. Am. J. Epidemiol. 2013, 178:38-45.
3. Wong V.W. Nonalcoholic fatty liver disease in Asia: a story of growth. J. Gastroenterol. Hepatol. 2013, 28:18-23.
4. Haslam D.W., James W.P. Obesity Lancet 2005, 366:1197-1209.
5. Zhan Y.T., An W. Roles of liver innate immune cells in nonalcoholic fatty liver disease. World J. Gastroenterol.: WJG 2010, 16:4652-4660.
6. Day C.P., James O.F. Steatohepatitis: a tale of two "hits"?. Gastroenterology 1998, 114:842-845.
7. Adams L.A., Angulo P., Lindor K.D. Nonalcoholic fatty liver disease. CMAJ: Can. Med. Assoc. J. = Journal de l'Association medicale canadienne 2005, 172:899-905.
8. Laplante M., Sabatini D.M. MTORC1 activates SREBP-1c and uncouples lipogenesis from gluconeogenesis. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:3281-3282.
9. Smith B.W., Adams L.A. Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment. Nat. Rev. Endocrinol. 2011, 7:456-465.
10. Wolowczuk I., Verwaerde C., Viltart O., Delanoye A., Delacre M., Pot B., et al. Feeding our immune system: impact on metabolism. Clin. Dev. Immunol. 2008, 2008:639803.
11. Su G.L. Lipopolysaccharides in liver injury: molecular mechanisms of Kupffer cell activation. Am. J. Physiol. Gastrointest. Liver Physiol. 2002, 283:G256-G265.
12. Hou X., Zhou R., Wei H., Sun R., Tian Z. NKG2D-retinoic acid early inducible-1 recognition between natural killer cells and Kupffer cells in a novel murine natural killer cell-dependent fulminant hepatitis. Hepatology 2009, 49:940-949.
13. Waldmann T.A. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat. Rev. Immunol. 2006, 6:595-601.
14. He Y.W., Malek T.R. The structure and function of gamma c-dependent cytokines and receptors: regulation of T lymphocyte development and homeostasis. Crit. Rev. Immunol. 1998, 18:503-524.
15. Dubois S., Mariner J., Waldmann T.A., Tagaya Y. IL-15Ralpha recycles and presents IL-15 In trans to neighboring cells. Immunity 2002, 17:537-547.
16. Lodolce J.P., Burkett P.R., Boone D.L., Chien M., Ma A. T cell-independent interleukin 15Ralpha signals are required for bystander proliferation. J. Exp. Med. 2001, 194:1187-1194.
17. Carson W.E., Giri J.G., Lindemann M.J., Linett M.L., Ahdieh M., Paxton R., et al. Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. J. Exp. Med. 1994, 180:1395-1403.
18. Giri J.G., Ahdieh M., Eisenman J., Shanebeck K., Grabstein K., Kumaki S., et al. Utilization of the beta and gamma chains of the IL-2 receptor by the novel cytokine IL-15. EMBO J. 1994, 13:2822-2830.
19. Lodolce J.P., Boone D.L., Chai S., Swain R.E., Dassopoulos T., Trettin S., et al. IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation. Immunity 1998, 9:669-676.
20. Kennedy M.K., Glaccum M., Brown S.N., Butz E.A., Viney J.L., Embers M., et al. Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J. Exp. Med. 2000, 191:771-780.
21. Fehniger T.A., Caligiuri M.A. Interleukin 15: biology and relevance to human disease. Blood 2001, 97:14-32.
22. Waldmann T.A., Tagaya Y. The multifaceted regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens. Annu. Rev. Immunol. 1999, 17:19-49.
23. Dubois S.P., Waldmann T.A., Muller J.R. Survival adjustment of mature dendritic cells by IL-15. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:8662-8667.
24. Kuwajima S., Sato T., Ishida K., Tada H., Tezuka H., Ohteki T. Interleukin 15-dependent crosstalk between conventional and plasmacytoid dendritic cells is essential for CpG-induced immune activation. Nat. Immunol. 2006, 7:740-746.
25. Crispe I.N. The liver as a lymphoid organ. Annu. Rev. Immunol. 2009, 27:147-163.
26. Bieghs V., Trautwein C. The innate immune response during liver inflammation and metabolic disease. Trends Immunol. 2013, 34:446-452.
27. Kumar V. NKT-cell subsets: promoters and protectors in inflammatory liver disease. J. Hepatol. 2013, 59:618-620.
28. Ramanathan S., Gagnon J., Leblanc C., Rottapel R., Ilangumaran S. Suppressor of cytokine signaling 1 stringently regulates distinct functions of IL-7 and IL-15 in vivo during T lymphocyte development and homeostasis. J. Immunol. 2006, 176:4029-4041.
29. Gui Y., Yeganeh M., Ramanathan S., Leblanc C., Pomerleau V., Ferbeyre G., et al. SOCS1 controls liver regeneration by regulating HGF signaling in hepatocytes. J. Hepatol. 2011, 55:1300-1308.
30. Nakamura A., Terauchi Y. Lessons from mouse models of high-fat diet-induced NAFLD. Int. J. Mol. Sci. 2013, 14:21240-21257.
31. Aprile M., Ambrosio M.R., D'Esposito V., Beguinot F., Formisano P., Costa V., et al. PPARG in human adipogenesis: differential contribution of canonical transcripts and dominant negative isoforms. PPAR Res. 2014, 2014:537865.
32. Zhang Y., Castellani L.W., Sinal C.J., Gonzalez F.J., Edwards P.A. Peroxisome proliferator-activated receptor-gamma coactivator 1alpha (PGC-1alpha) regulates triglyceride metabolism by activation of the nuclear receptor FXR. Genes Dev. 2004, 18:157-169.
33. Li H.H., Tyburski J.B., Wang Y.W., Strawn S., Moon B.H., Kallakury B.V., et al. Modulation of fatty acid and bile acid metabolism by peroxisome proliferator-activated receptor alpha protects against alcoholic liver disease. Alcohol. Clin. Exp. Res. 2014.
34. Morris E.M., Jackman M.R., Meers G.M., Johnson G.C., Lopez J.L., MacLean P.S., et al. Reduced hepatic mitochondrial respiration following acute high-fat diet is prevented by PGC-1alpha overexpression. Am. J. Physiol. Gastrointest. Liver Physiol. 2013, 305:G868-G880.
35. Sell H., Habich C., Eckel J. Adaptive immunity in obesity and insulin resistance. Nat. Rev. Endocrinol. 2012, 8:709-716.
36. Tosello-Trampont A.C., Landes S.G., Nguyen V., Novobrantseva T.I., Hahn Y.S. Kuppfer cells trigger nonalcoholic steatohepatitis development in diet-induced mouse model through tumor necrosis factor-alpha production. J. Biol. Chem. 2012, 287:40161-40172.
37. Martin-Murphy B.V., You Q., Wang H., De La Houssaye B.A., Reilly T.P., Friedman J.E., et al. Mice lacking natural killer T cells are more susceptible to metabolic alterations following high fat diet feeding. PLoS ONE 2014, 9:e80949.
38. McInnes I.B., Liew F.Y. Interleukin 15: a proinflammatory role in rheumatoid arthritis synovitis. Immunol. Today 1998, 19:75-79.
39. Yokoyama S., Watanabe N., Sato N., Perera P.Y., Filkoski L., Tanaka T., et al. Antibody-mediated blockade of IL-15 reverses the autoimmune intestinal damage in transgenic mice that overexpress IL-15 in enterocytes. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:15849-15854.
40. Bobbala D., Chen X.L., Leblanc C., Mayhue M., Stankova J., Tanaka T., et al. Interleukin-15 plays an essential role in the pathogenesis of autoimmune diabetes in the NOD mouse. Diabetologia 2012, 55:3010-3020.
41. Nguyen P., Leray V., Diez M., Serisier S., Le Bloc'h J., Siliart B., et al. Liver lipid metabolism. J. Animal Physiol. Animal Nutr. 2008, 92:272-283.
42. Browning J.D., Horton J.D. Molecular mediators of hepatic steatosis and liver injury. J. Clin. Invest. 2004, 114:147-152.
43. Wheeler M.C., Gekakis N. Hsp90 modulates PPARgamma activity in a mouse model of non-alcoholic fatty liver disease. J. Lipid Res. 2014.
44. Moran-Salvador E., Lopez-Parra M., Garcia-Alonso V., Titos E., Martinez-Clemente M., Gonzalez-Periz A., et al. Role for PPARgamma in obesity-induced hepatic steatosis as determined by hepatocyte- and macrophage-specific conditional knockouts. FASEB J. 2011, 25:2538-2550.
45. Lefebvre P., Chinetti G., Fruchart J.C., Staels B. Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis. J. Clin. Invest. 2006, 116:571-580.
46. Assimacopoulos-Jeannet F., Thumelin S., Roche E., Esser V., McGarry J.D., Prentki M. Fatty acids rapidly induce the carnitine palmitoyltransferase I gene in the pancreatic beta-cell line INS-1. J. Biol. Chem. 1997, 272:1659-1664.
47. Kanegane H., Tosato G. Activation of naive and memory T cells by interleukin-15. Blood 1996, 88:230-235.
48. Stoklasek T.A., Schluns K.S., Lefrancois L. Combined IL-15/IL-15Ralpha immunotherapy maximizes IL-15 activity in vivo. J. Immunol. 2006, 177:6072-6080.
49. Golden-Mason L., Kelly A.M., Doherty D.G., Traynor O., McEntee G., Kelly J., et al. Hepatic interleuklin 15 (IL-15) expression: implications for local NK/NKT cell homeostasis and development. Clin. Exp. Immunol. 2004, 138:94-101.
50. Correia M.P., Cardoso E.M., Pereira C.F., Neves R., Uhrberg M., Arosa F.A. Hepatocytes and IL-15: a favorable microenvironment for T cell survival and CD8+ T cell differentiation. J. Immunol. 2009, 182:6149-6159.
51. Christiansen T., Paulsen S.K., Bruun J.M., Pedersen S.B., Richelsen B. Exercise training versus diet-induced weight-loss on metabolic risk factors and inflammatory markers in obese subjects: a 12-week randomized intervention study. Am. J. Physiol. Endocrinol. Metab. 2010, 298:E824-E831.
52. Barra N.G., Reid S., MacKenzie R., Werstuck G., Trigatti B.L., Richards C., et al. Interleukin-15 contributes to the regulation of murine adipose tissue and human adipocytes. Obesity (Silver Spring. 2010, 18:1601-1607.
53. Exley M.A., Koziel M.J. To be or not to be NKT: natural killer T cells in the liver. Hepatology 2004, 40:1033-1040.
54. Lalor P.F., Faint J., Aarbodem Y., Hubscher S.G., Adams D.H. The role of cytokines and chemokines in the development of steatohepatitis. Semin. Liver Dis. 2007, 27:173-193.
55. + T cells by the normal liver. J. Immunol. 1999, 163:3202-3210.
56. Ring A.M., Lin J.X., Feng D., Mitra S., Rickert M., Bowman G.R., et al. Mechanistic and structural insight into the functional dichotomy between IL-2 and IL-15. Nat. Immunol. 2012, 13:1187-1195.
57. Kahraman A., Schlattjan M., Kocabayoglu P., Yildiz-Meziletoglu S., Schlensak M., Fingas C.D., et al. Major histocompatibility complex class I-related chains A and B (MIC A/B): a novel role in nonalcoholic steatohepatitis. Hepatology 2010, 51:92-102.
58. Guebre-Xabier M., Yang S., Lin H.Z., Schwenk R., Krzych U., Diehl A.M. Altered hepatic lymphocyte subpopulations in obesity-related murine fatty livers: potential mechanism for sensitization to liver damage. Hepatology 2000, 31:633-640.
59. Kremer M., Hines I.N. Natural killer T cells and non-alcoholic fatty liver disease: fat chews on the immune system. World J. Gastroenterol.: WJG 2008, 14:487-488.
60. Tajiri K., Shimizu Y., Tsuneyama K., Sugiyama T. Role of liver-infiltrating CD3+ CD56+ natural killer T cells in the pathogenesis of nonalcoholic fatty liver disease. Eur. J. Gastroenterol. Hepatol. 2009, 21:673-680.
61. Lynch L., Nowak M., Varghese B., Clark J., Hogan A.E., Toxavidis V., et al. Adipose tissue invariant NKT cells protect against diet-induced obesity and metabolic disorder through regulatory cytokine production. Immunity 2012, 37:574-587.
62. Rutkowski M.D., DeLeo J.A. The role of cytokines in the initiation and maintenance of chronic pain. Drug News Perspect 2002, 15:626-632.
63. Maltby J., Wright S., Bird G., Sheron N. Chemokine levels in human liver homogenates: associations between GRO alpha and histopathological evidence of alcoholic hepatitis. Hepatology 1996, 24:1156-1160.
64. Kirovski G., Gabele E., Dorn C., Moleda L., Niessen C., Weiss T.S., et al. Hepatic steatosis causes induction of the chemokine RANTES in the absence of significant hepatic inflammation. Int. J. Clin. Exp. Pathol. 2010, 3:675-680.
65. Moriconi F., Christiansen H., Raddatz D., Dudas J., Hermann R.M., Rave-Frank M., et al. Effect of radiation on gene expression of rat liver chemokines: in vivo and in vitro studies. Radiat. Res. 2008, 169:162-169.
66. Huang W., Metlakunta A., Dedousis N., Zhang P., Sipula I., Dube J.J., et al. Depletion of liver Kupffer cells prevents the development of diet-induced hepatic steatosis and insulin resistance. Diabetes 2010, 59:347-357.
67. Hijikawa T., Kaibori M., Uchida Y., Yamada M., Matsui K., Ozaki T., et al. Insulin-like growth factor 1 prevents liver injury through the inhibition of TNF-alpha and iNOS induction in d-galactosamine and LPS-treated rats. Shock 2008, 29:740-747.
68. Tolman K.G., Dalpiaz A.S. Treatment of non-alcoholic fatty liver disease. Ther. Clin. Risk Manage. 2007, 3:1153-1163.